Genomic polymorphisms of drug metabolisms associated with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with gemcitabine (GEM) or taxanes.

被引：0
|
作者：
Zhang, L. [1 ]
Zhou, C. [1 ]
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Shanghai 200092, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7627
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7627
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Predictive model for survival in advanced non-small cell lung cancer (NSCLC) treated with frontline pembrolizumab
    Mielgo Rubio, X.
    Olmedo Garcia, M. E.
    Sereno Moyano, M.
    Aguado, C.
    Nunez, J. A.
    Domine Gomez, M.
    Sanchez Pena, A. M.
    Nalda Ariza, I.
    Cerezo Gonzalez, S.
    Alvarez Cabellos, R.
    Cabezon Gutierrez, L.
    Pangua Mendez, C.
    Cervera, R.
    Calles Blanco, A.
    Lopez Castro, R.
    Sanchez Torres, J. M.
    Lopez Martin, A.
    Velastegui Ordonez, A.
    Fernandez, E. Perez
    Cruz, P.
    ANNALS OF ONCOLOGY, 2019, 30 : 514 - 514
  • [22] Prognostic Factors for Overall Survival among Patients with Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Verleger, Katharina
    Treur, Maarten
    Penrod, John
    Daumont, Melinda
    Lees, Michael
    Macahilig, Cynthia
    Solem, Caitlyn
    Jiang, Shan
    Chirita, Oana
    Hertel, Nadine
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S995 - S996
  • [23] Progression-free survival (PFS) and overall survival (OS) in phase HI trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Hotta, K.
    Kiura, K.
    Takigawa, N.
    Tabata, M.
    Fujiwara, Y.
    Tanimoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] Polymorphisms in MicroRNAs Are Associated with Survival in Non-Small Cell Lung Cancer
    Zhao, Yang
    Wei, Qingyi
    Hu, Lingming
    Chen, Feng
    Hu, Zhibin
    Heist, Rebecca S.
    Su, Li
    Amos, Christopher I.
    Shen, Hongbing
    Christiani, David C.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2014, 23 (11) : 2503 - 2511
  • [25] Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC)
    Cramer-van der Welle, Christine
    Peters, Bas J. M.
    Deenen, Maarten J.
    Schramel, Franz M. N. H.
    Van de Garde, Ewoudt M. W.
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [26] Effect of BRM Promoter Polymorphisms on Survival Outcomes of Platinum-Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Cuffe, Sinead
    Cheng, Lu
    Azad, Abul Kalam
    Brhane, Yonathan
    Cheng, Dangxiao
    Chen, Zhuo
    Qiu, Xiaoping
    Boyd, Kevin
    Xu, Wei
    Shepherd, Frances A.
    Tsao, Ming-Sound
    Reisman, David
    Liu, Geoffrey
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 325 - 326
  • [27] Non-examination of lymph nodes (LN) and overall survival (OS) in non-small cell lung cancer (NSCLC) patients.
    Jemal, Ahmedin
    Lin, Chun Chieh
    Smeltzer, Matthew
    Osarogiagbon, Raymond U.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Impact of immune-related adverse events (irAE) on overall survival (OS) in patients treated with immunotherapy for non-small cell lung cancer (NSCLC).
    Owen, Dwight Hall
    Wei, Lai
    Villalona-Calero, Miguel Angel
    Bertino, Erin Marie
    He, Kai
    Shields, Peter G.
    Carbone, David P.
    Otterson, Gregory Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Gemcitabine (GEM) as rescue treatment of advanced non small cell lung cancer (NSCLC). Effect on brain metastasis
    Cassano, A
    Corsi, DC
    Pozzo, C
    Angelelli, L
    Ferretti, G
    Longo, R
    Barone, C
    ANNALS OF ONCOLOGY, 1998, 9 : 163 - 163
  • [30] Gemcitabine(GEM) in advanced non small cell lung cancer (NSCLC) of elderly. A phase II study
    Pasquini, E
    Tassinari, D
    Nicolini, M
    Gianni, L
    Oliverio, G
    Tononi, A
    Papi, M
    Drudi, G
    Panzini, I
    Ravaioll, A
    ANNALS OF ONCOLOGY, 1998, 9 : 32 - 32
12345